You are here:

adalimumab 40mg solution for injection (Humira)


Following a full submission

adalimumab (Humira®) is not recommended for use within NHS Scotland for the treatment of severe, active Crohn’s disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

In both induction and maintenance studies in patients with severe active Crohn’s disease, more patients treated with adalimumab achieved and maintained clinical remission than with placebo. However, the manufacturer did not present a sufficiently robust economic case to gain acceptance by the SMC.

Drug Details

Drug Name: adalimumab 40mg solution for injection (Humira)
SMC Drug ID: 417/07
Manufacturer: Abbott Laboratories
Indication: Severe active crohn’s disease
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Full submission
Status: Superseded
Date Advice Published: 12 November 2007